EP0007450A1
(de)
*
|
1978-07-07 |
1980-02-06 |
Ciba-Geigy Ag |
Azatetracyclische Carbonitrile, ihre Herstellung, pharmazeutische Präparate, die diese enthalten und deren Verwendung
|
EP0030916B1
(de)
*
|
1979-12-10 |
1984-08-29 |
Ciba-Geigy Ag |
Azatetracyclische Carbonitrile
|
FR2504140A1
(fr)
*
|
1981-04-16 |
1982-10-22 |
Centre Nat Rech Scient |
Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
|
DE3372369D1
(de)
*
|
1982-05-18 |
1987-08-13 |
Hoffmann La Roche |
Pyrrole (3,4-d)(2)benzazepine derivatives
|
JPS62101941U
(sv)
*
|
1985-12-16 |
1987-06-29 |
|
|
IE62754B1
(en)
*
|
1988-08-26 |
1995-02-22 |
Akzo Nv |
Tetracyclic antidepressants
|
EP0569096A1
(en)
*
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
JP2710695B2
(ja)
*
|
1993-04-06 |
1998-02-10 |
アボツト・ラボラトリーズ |
ドーパミンアゴニストとしての四環式化合物
|
ATE167057T1
(de)
*
|
1994-03-02 |
1998-06-15 |
Akzo Nobel Nv |
Sublinguales oder bukkales arzneimittel
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
US6057441A
(en)
*
|
1996-04-12 |
2000-05-02 |
Janssen Pharmaceutica, N.V. |
Substituted tetracyclic tetrahydrofuran derivatives
|
HUP0002106A3
(en)
*
|
1997-05-26 |
2001-11-28 |
Akzo Nobel Nv |
Aromatic sulfonates of trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pyrrole and pharmaceutical compositions containing it
|
HRP20020305A8
(en)
*
|
2002-04-10 |
2009-03-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
|
HRP20020441A2
(en)
*
|
2002-05-21 |
2003-12-31 |
Pliva D D |
1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
|
HRP20030160A2
(en)
*
|
2003-03-06 |
2005-04-30 |
Pliva-Istra�iva�ki institut d.o.o. |
1-thiadibenzoazulene derivatives and biological action thereof
|
WO2004100992A2
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
HRP20030885A2
(en)
*
|
2003-11-03 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
|
HRP20030958A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030956A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
|
HRP20030959A2
(sv)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
|
HRP20030957A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030955A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030953A2
(en)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030954A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva D.D. |
USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20040104A2
(en)
*
|
2004-01-30 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
|
CN1917882A
(zh)
*
|
2004-02-13 |
2007-02-21 |
辉瑞产品公司 |
非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
|
MXPA06013163A
(es)
*
|
2004-05-11 |
2007-02-13 |
Pfizer Prod Inc |
Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
|
EP1802301A1
(en)
*
|
2004-10-15 |
2007-07-04 |
Pfizer Inc. |
Treatment of bipolar disorders and associated symptoms
|
DE602006010132D1
(de)
*
|
2005-04-07 |
2009-12-17 |
Organon Nv |
Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol
|
TWI364423B
(en)
*
|
2005-04-07 |
2012-05-21 |
Msd Oss Bv |
Crystal form of asenapine maleate
|
US7872147B2
(en)
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
US7741358B2
(en)
*
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
WO2007046554A1
(ja)
*
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
TW200817414A
(en)
*
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
US7750167B2
(en)
*
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
US20080090892A1
(en)
*
|
2006-10-06 |
2008-04-17 |
N.V. Organon |
Amorphous asenapine and processes for preparing same
|
US7875729B2
(en)
*
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
EP2170399A1
(en)
*
|
2007-06-05 |
2010-04-07 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
JP5245428B2
(ja)
*
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
JP2011508751A
(ja)
*
|
2008-01-04 |
2011-03-17 |
ナームローゼ・フエンノートチヤツプ・オルガノン |
アセナピンの調製方法および前記方法において使用される中間生成物
|
WO2009104080A2
(en)
|
2008-02-20 |
2009-08-27 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
EP2321011A1
(en)
*
|
2008-06-25 |
2011-05-18 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
MX2012000061A
(es)
|
2009-06-24 |
2012-06-01 |
Msd Oss Bv |
Formulaciones inyectables que contienen asenapina, y metodo de tratamiento usando las mismas.
|
TW201118102A
(en)
|
2009-07-29 |
2011-06-01 |
Organon Nv |
Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
|
WO2011159903A2
(en)
|
2010-06-18 |
2011-12-22 |
Dr. Reddy's Laboratories Ltd. |
Asenapine maleate
|
EP2598496B1
(en)
|
2010-07-29 |
2014-03-19 |
Laboratorios Lesvi, S.L. |
Novel process for the preparation of asenapine
|
CN103313712B
(zh)
|
2010-11-15 |
2016-10-26 |
艾吉因生物股份有限公司 |
用于治疗认知障碍的哒嗪衍生物、组合物和方法
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
ES2575544T3
(es)
|
2010-12-24 |
2016-06-29 |
Medichem, S.A. |
Procedimientos para la preparación de 5-cloro-2-metil-2,3,3a,12b-tetrahidro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pirrol
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
ITMI20110734A1
(it)
|
2011-05-02 |
2012-11-03 |
Olon Spa |
Sali cristallini di asenapina
|
EP2524921A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
EP2524919A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
JP6014656B2
(ja)
|
2011-05-18 |
2016-10-25 |
ラビラトリオス レスビ エス エレ |
化合物の多形体
|
WO2012156676A1
(en)
|
2011-05-18 |
2012-11-22 |
Laboratorios Lesvi S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
WO2013011461A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
US20140336391A1
(en)
|
2011-11-28 |
2014-11-13 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine intermediate
|
CN103254201B
(zh)
*
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
WO2013190481A1
(en)
*
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
CN103113379A
(zh)
*
|
2013-03-12 |
2013-05-22 |
盛世泰科生物医药技术(苏州)有限公司 |
阿塞那平马来酸盐的合成工艺
|
CN103351393B
(zh)
*
|
2013-07-03 |
2016-04-06 |
华裕(无锡)制药有限公司 |
用于制备阿森那平之还原剂及阿森那平之制备方法
|
JP6883988B2
(ja)
|
2013-12-20 |
2021-06-09 |
エージンバイオ, インコーポレイテッド |
ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
|
CN103772400A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
CN103772401A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
CA2987081C
(en)
|
2015-06-11 |
2022-08-30 |
Alrise Biosystems Gmbh |
Process for the preparation of drug loaded microparticles
|
IL256354B
(en)
|
2015-06-19 |
2022-09-01 |
Agenebio Inc |
History of benzodiazepines, preparations and their use for the treatment of cognitive impairment
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
CA3047354A1
(en)
|
2016-12-20 |
2018-06-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
|
EP3558275A1
(en)
|
2016-12-20 |
2019-10-30 |
LTS Lohmann Therapie-Systeme AG |
Transdermal therapeutic system containing asenapine
|
EP3644973B1
(en)
|
2017-06-26 |
2021-03-24 |
LTS LOHMANN Therapie-Systeme AG |
Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
|
EA202190076A1
(ru)
|
2018-06-19 |
2021-09-22 |
Эйджинбайо, Инк. |
Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
|
CN112704672A
(zh)
|
2018-06-20 |
2021-04-27 |
罗曼治疗系统股份公司 |
含有阿塞那平的透皮治疗系统
|
CN110183457A
(zh)
*
|
2019-06-27 |
2019-08-30 |
浙江天顺药业有限公司 |
一种阿塞那平及其制备方法
|
CN112830931A
(zh)
|
2019-08-13 |
2021-05-25 |
浙江奥翔药业股份有限公司 |
制备阿塞那平的方法
|
US11679407B2
(en)
*
|
2020-06-26 |
2023-06-20 |
Intel Corporation |
Liquid metal thermal interface material application
|
WO2023006954A1
(en)
|
2021-07-30 |
2023-02-02 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Asenapine for use in cancer
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|